Noah Stansfield

Nurses Jeffrey Hernandez, DNP, APRN, and Bonnie Blain, RN, discussed important behind the scenes work nurses carry out in neurology care.

German 3-year real-world data shows ozanimod keeps RRMS relapses low, disability stable, and safety consistent in routine care.

Nurses Jeffrey Hernandez, DNP, APRN, and Bonnie Blain, RN, discussed the unique role of nurses in neurology, from their perspective working with patients with MS.

Hybridopa improved MDS-UPDRS scores in a small phase 2a Parkinson disease trial, with phase 3 testing planned for 2026.

The registered nurse at the University of Miami and the president of the IOMSN discussed advice for younger colleagues, misconceptions about neurology nursing, and more. [WATCH TIME: 10 minutes]

New RESTORE-FA results show DT-216P2 improved balance and fatigue within 4 weeks, with tolerable safety.

The registered nurse at the University of Miami and the president of the IOMSN shared their thoughts on the unique demands of nursing in neurology, with a particular focus on their experience in multiple sclerosis nursing. [WATCH TIME: 6 minutes]

Thomas Crawford, MD, a pediatric neurologist at Johns Hopkins, discussed the FDA's recent approval of high-dose nusinersen for spinal muscular atrophy and SMA's evolving landscape of care.

The pediatric neurologist at Johns Hopkins Medicine provided commentary on the FDA's decision, and also discussed the evolving SMA treatment landscape in general terms. [WATCH TIME: 11 minutes]

Srikanth Muppidi, MD, a clinical professor of adult neurology at Stanford University, discussed phase 2 findings from the KYSA-6 trial of mivocabtagene autoleucel (miv-cel; KYV-101) in MG.

Amanda Piquet, MD, FAAN, spoke about data she presented at AAN's 2026 Meeting.

The clinical professor of adult neurology at Stanford University discussed data he presented at AAN's 2026 Meeting [WATCH TIME: 4 minutes]

The director of the autoimmune neurology program at the University of Colorado discussed data she presented at AAN's 2026 Meeting [WATCH TIME: 5 minutes]

Data show ofatumumab maintains a steady safety profile in relapsing MS, with low serious infections, stable labs, and durable biomarker improvements.

Semaglutide shows CNS biomarker shifts in early Alzheimer disease, lowering CSF tau and neurogranin while reshaping immune signals, as per new AAN data report.

In observance of International Pompe Day, held annually on April 15, catch up on the past year’s news and expert insights related to this rare disease.

FDA accepts Ultragenyx’s UX111 gene therapy BLA for Sanfilippo A, setting a September 2026 decision date.

The chief research officer of the Muscular Dystrophy Association spoke on the FDA's approval of a high-dose regimen of nusinersen and how it fits into an increasingly complex treatment landscape. [WATCH TIME: 11 minutes]

The professor of neurology at Mayo Clinic spoke about the current state of biomarker research in MSA. [WATCH TIME: 8 minutes]

BridgeBio Pharma has submitted a new drug application to the FDA for BBP-418 for the treatment of limb-girdle muscular dystrophy type 2I/R9, supported by interim phase 3 trial data.

Wolfgang Singer, MD, a professor of neurology at Mayo Clinic, spoke about the current state of biomarker research in MSA.

Phase 2 findings indicated that the investigational agent zervimesine exhibited a favorable safety profile and may slow disease progression in patients with mild to moderate dementia with Lewy bodies.

The chief research officer of the Muscular Dystrophy Association spoke on highlights and themes from the organization's 2026 Clinical and Scientific Conference. [WATCH TIME: 9 minutes]

MRI-guided focused ultrasound steers IV gene therapy to mouse brains, lowering cortical tau—though hippocampal response stays absent.

The child neurologist at Children’s Hospital of Philadelphia discussed the real-world safety data of givinostat use in patients with Duchenne muscular dystrophy at the 2026 MDA Conference. [WATCH TIME: 5 minutes]

Early BB-301 gene therapy data show durable swallowing gains and benign safety in OPMD dysphagia, hinting at disease modification.

Phase 3 data show Ultragenyx’s DTX301 gene therapy lowers ammonia in OTC deficiency, easing symptoms and reducing reliance on restrictive diets.

The agency has set a PDUFA date for August 22, 2026.

Polish real-world study shows children with SMA improve after switching from nusinersen or risdiplam to gene therapy, with expected side effects.

A first-in-human SMA1 gene therapy trial doses infants with GB221 via intracisternal AAV delivery, aiming to boost motor outcomes while limiting toxicity.